Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468880 | 0.93 | DRD2 (0.46) | DRD2DRD1SIGMAR1HTR1AHTR2A | |
| SCHEMBL12469081 | 0.86 | KCNH2 (0.58) | DRD2DRD1SIGMAR1HTR1AHTR2A | |
| SCHEMBL12468808 | 0.79 | DRD2 (0.58) | DRD2HTR1AHTR2ADRD3HTR7 | |
| SCHEMBL12468732 | 0.79 | DRD2 (0.54) | DRD2SIGMAR1HTR1AHTR2ADRD5 | |
| SCHEMBL12469195 | 0.79 | KCNH2 (0.54) | DRD1SIGMAR1HTR1ADRD3SLC6A3 | |
| SCHEMBL12469349 | 0.74 | SLC6A2 (0.56) | SIGMAR1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL28161148 | 0.74 | BCL2A1 (0.67) | DRD2SIGMAR1BCL2A1DRD3SLC6A2 | |
| SCHEMBL11938912 | 0.73 | KDM4E (0.68) | DRD2SIGMAR1BCL2A1HTR1AHTR2A | |
| SCHEMBL15348353 | 0.72 | HTR7 (0.48) | DRD2HTR1AHTR2AHTR7HTR6 | |
| SCHEMBL12469282 | 0.72 | DRD2 (0.56) | DRD2HTR1AHTR2ADRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012051601-A2 | HETEROARYLTHIO COMPOUNDS | EPIOMED THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | NLN, HTT, ABAT | DRD2 2163/4885DRD1 3523/4885SIGMAR1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.